[Abstract, Methods, Mixed]

Hmga2 functions as a competing endogenous RNA to promote lung cancer progression. Non-small cell lung cancer (NSCLC) is the most prevalent histological cancer subtype worldwide1. As the majority of patients present with invasive, metastatic disease2, it is vital to understand the basis for lung cancer progression. Hmga2 is highly expressed in metastatic lung adenocarcinoma where it contributes to cancer progression and metastasis3-6. Here we show that Hmga2 promotes lung cancer progression by operating as a competing endogenous RNA (ceRNA)7-11 for the let-7 microRNA (miRNA) family. Hmga2 can promote the transformation of lung cancer cells independent of protein-coding function but dependent upon the presence of let-7 sites; this occurs without changes in the levels of let-7 isoforms, suggesting that Hmga2 affects let-7 activity by altering miRNA targeting. These effects are further observed in vivo, where Hmga2 ceRNA activity drives lung cancer growth, invasion and dissemination. Integrated analysis of miRNA target prediction algorithms and metastatic lung cancer gene expression data reveals the TGF-b co-receptor Tgfbr312 as a putative target of Hmga2 ceRNA function. Tgfbr3 expression is regulated by the Hmga2 ceRNA via differential recruitment to Argonaute-2 (Ago2), and TGF-b signalling driven by Tgfbr3 is largely necessary for Hmga2 to promote lung cancer progression. Finally, analysis of NSCLC patient gene expression data reveals that HMGA2 and TGFBR3 are co-ordinately regulated in NSCLC patient material, a vital corollary to ceRNA function. Taken together, these results suggest that Hmga2 promotes lung carcinogenesis as both a protein-coding gene and a non-coding RNA; such dual-function regulation of gene expression networks reflects a novel means by which oncogenes promote disease progression.

Online-only Methods
Cell lines
368T1 and 482N1 cells were generated previously6. KPD F/- and -/- sarcoma cells were a kind gift of Phillip A. Sharp24. Cancer Research UK Cell Services provided HEK293, Phoenix ampho, NCI-H1299, and SK-MES-1 cells. All cell lines were cultured in DMEM medium with 10% FBS, 10 mM glutamine and 1% penicillin and streptomycin at 37degC in a 5% CO2/95% air incubator.
Drug and reagent treatment
For Western, luciferase, qRT-PCR, and BrdU analysis, 368T1 cells were co-treated with 2 ng/mL TGF-b and either DMSO or 2.5 mM SB-431542 ("SB") and 482N1 cells were treated with either DMSO or 2.5 mM SB-431542 for 24 hours. For soft agar analysis, cells were fed with media containing either DMSO or SB.
For Western analyses, 368T1 and 482N1 cells were plated (2.5 x 105 cells) into 6-well plates overnight. Cells were then treated with DMSO, 1 mM AZD6244 or 1 mM PIK-75 for two hours and lysates were prepared.
Lentivirus and retrovirus production
Short hairpin RNA (shRNA) lentiviruses (which are listed in Supplementary Table 1) were generated by co-transfection of HEK293 cells with shRNA vector and packaging vectors pCMV-VSVG and pCMV-8.2. MSCV-based retroviruses were generated by transfection of Phoenix ampho cells with retroviral vectors. 48 and 72 hours after transfection, virus particles in the medium were harvested, filtered, and transduced onto cells.
Stable cell line generation
Expression vectors were initially linearized overnight using BglII. Linearised DNA was then transfected into cells in 24-well plates, with media replaced six hours later. Cells were then replated into 6-well plates in the presence of 500 mg/mL G418 for selection over two weeks. For lentiviral and retroviral infection, cells were infected in 6-well plates and subsequently split into 10 cm dishes in the presence of 2.5 mg/mL puromycin for selection over 72 hours.
Western blotting
Western blotting was performed by standard methods. Antibody details are provided in Supplementary Table 2.
qRT-PCR
RNA was isolated using RNA-Bee using manufacturers' instructions. Both standard and miRNA-specific qRT-PCR was performed using QuantiTect SYBR Green primers as per manufacturers' instructions (QIAGEN). Primer details are provided in Supplementary Table 3.
Luciferase assays
CAGA12
Cells were seeded into 96-well plates in triplicate and co-transfected with pRL-TK (Promega) and either control pGL3 or the TGF-b reporter pCAGA12-GL322. 24 hours later, luciferase activities were determined using the Dual-Luciferase Assay System as per manufacturers' instructions (Promega).
Tgfbr3 3' UTR
Cells were seeded into 96-well plates in triplicate and co-transfected with pGL3 (Promega) and either the control pRL-CXCR430 or the wild type/mutant fragment of the Tgfbr3 3' UTR. Luciferase activities were determined as above.
BrdU analysis
Cells were plated in triplicate into six-well plates overnight (2.5 x 105 cells per well). They were then treated with 10 mM BrdU for one hour, trypsinized, washed in PBS and stained for BrdU/DAPI analysis using standard methods by the Cancer Research UK Flow Cytometry Facility.
siRNA/miRNA transfection
Cells were transfected with siRNA/miRNA as described previously29. Cells were subsequently plated into soft agar assays as above or harvested for RNA/protein as above.
polyHEMA plating analysis
6-well plates were either mock coated or coated with (polyHEMA) as previously described31. Cells were subsequently plated into these 6-wells overnight and BrdU analysis was performed as described above.
Histopathological analysis
After sacrifice by CO2 asphyxiation, lungs were collected from animals and fixed overnight in 10% formalin. They were subsequently placed in 70% ethanol and submitted for embedding, sectioning, and hematoxylin and eosin (H&E) staining.
In vitro transcription
TOPO cloned fragments of Hmga2 and Tgfbr3 were in vitro transcribed using the SP6 MAXIscript kit as per manufacturers' instructions (Ambion). RNA was subsequently purified using the RNEasy cleanup kit as per manufacturers' instructios (Qiagen).
Transcript copy number analysis
For determination of transcript copy number, RNA was prepared from 2 x 106 482N1 cells using RNA Bee as described above. qRT-PCR was performed for Hmga2, Tgfbr3, and let-7a/c/e/f/i as described above. CT values were compared to a two-fold dilution series of either in vitro transcribed Hmga2/Tgfbr3 or synthetic let-7a/c/e/f/i miRNA mimics (Qiagen). Moles of transcript and copies of transcript per cell were then calculated using standard stoichiometric methods. Confidence intervals were calculated using a t-statistic.
RNA library production and next-generation sequencing (RNA-seq)
Total RNA was generated from the 482N1 Hmga2 allelic series (with biological triplicates) as described above. The Total RNA samples were initially quality controlled (QC) using the 6000 Nano RNA Chip on the BioAnalyser 2100 (Agilent, Santa Clara, CA, USA) to ensure RNA integrity and estimate concentration before starting the procedure. If the samples passed the initial QC the Total RNA samples were subjected to poly-A selection using Sera-Mag oligo (dT) beads (Thermo Fisher Scientific Inc.), and the bound poly-A RNA species utilized for downstream library prep using the Illumina mRNA kit RS-122-2101 (TruSeq Stranded mRNA Sample Prep. Illumina San Diego, CA, USA). The standard PCR cycles suggested in the protocol were also altered to match the concentration of the total RNA from the initial QC. After production of the mRNA libraries a final QC was performed on a DNA 1000 chip using the BioAnalyser 2100 (Agilent, Santa Clara, CA, USA). If the mRNA libraries passed the QC they were ready for flow cell cluster formation on a cBot and then 100 b.p. Paired End (PE) sequencing by synthesis on the HiSeq 2500 was performed.
RNA-seq data processing and analyses
We aligned 100 b.p. paired-end sequencing reads to the mouse genome (mm9, UCSC) using Tophat2/Bowtie232 allowing for 5 mismatches, a mate-inner-distribution of -40 and a mate-standard-deviation of 50. These library fragment metrics were derived from an alignment of 5e5 sampled reads to the mouse transcriptome. We identified read-pair mappings to gene structures derived from RefSeq (RefGene table, UCSC) using the summarizeOverlaps function with mode IntersectStrict (GenomicRanges, Bioconductor). This generated a mean fragments per sample value of 33.5e6. Using these raw counts we identified genes expressed across the sample groups. We removed genes with a count <= 10 across all samples prior to statistical analysis. The differential analysis was carried out using edgeR33 applying TMM library normalisation and a 0.0005 false discovery rate (fdr) to select expressed transcripts. In addition, we calculated gene level fragments per kilobase of exon per million fragments mapped (FPKM) values for the same gene set using Cufflinks34.
Sylamer analysis
A list of Ensembl gene IDs was generated from the set of transcripts expressed in the samples described above. This set of transcripts was then placed in rank order by their differential expression between two groups and analysed using the Sylamer algorithm via the SylArray platform17. A Sylamer plot was then generated for all 8mer miRNA strings whose target sites were enriched significantly (p<0.001 by hypergeometric testing).
Statistical testing
Unless otherwise specified, statistical significance was assessed by the Student's t-test.
Vector cloning
Hmga2
pCDNA3.1-Hmga2 wt and Hmga2 m7 ("wt" and "m7") were acquired from Addgene (Plasmid nos. 14789 and 14792)13. In order to generate pCDNA3.1-Hmga2 ATG wt and pCDNA3.1-Hmga2 ATG m7 ("ATG wt" and "ATG m7"), the wt and m7 constructs were mutated by site-directed mutagenesis as per manufacturers' instructions (Stratagene) using primers 5'-GGTAGCGGCGGCGGGAGGCAGGCTGAGCGCACGCGGTGAGG-3' and 5'-CCTCACCGCGTGCGCTCAGCCTGCCTCCCGCCGCCGCTACC-3'. For generation of 482N1 shHmga2 stable cell lines, "wt", "m7", "ATG wt" and "ATG m7" the shRNA binding site was mutated using primers 5'-CCATTTCTGCAAGCTAAGTATGTTTGCAGGAGCCCCGGCTCCGGACGCGTAACTG CATCCAACTTTCTCC-3' and 5'-GGAGAAAGTTGGATGCAGTTACGCGTCCGGAGCCGGGGCTCCTGCAAACATACT TAGCTTGCAGAAATGG-3'.
pRL-Tgfbr3
A fragment containing the Tgfbr3 3'UTR was PCR amplified from 482N1 cDNA using primers 5'-TAAGAACTCGAGCTGCGTGTGTTCTCCGCAG-3' and 5'-TAACAAGCGGCCGCCTGTCAGTTTAATGAACGAACC-3'. Both the PCR product and pRL-CXCR4 were digested with XhoI and NotI and ligated together to generate pRL-Tgfbr3. The let-7 mutant was generated by site-directed mutagenesis as above using primers 5'-GCAGGCGCGTGCCTGTCTTTTTGTACTGTAACGGGCTCATGGTTTGAATGATGAG CGTACTGCTGGTTG-3' and 5'-CAACCAGCAGTACGCTCATCATTCAAACCATGAGCCCGTTACAGTACAAAAAGA CAGGCACGCGCCTGC-3'.
Hmga2-TOPO/Tgfbr3-TOPO
A fragment containing the Hmga2 cDNA sequence recognized by the respective qRT-PCR primers was PCR amplified from 482N1 cDNA using primers 5'-CTACATCCCGTCTCCCGAAAGGTGCTGG-3' and 5'-GGATCCGGTAGAAATTGAATGTCGGCGCCCCCTAATC-3'. A fragment containing the Tgfbr3 cDNA sequence recognized by the respective qRT-PCR primers was PCR amplified from 482N1 cDNA using primers 5'-CTCGAGCAGAAGAAGTGCAAGGGGGCGTGAATATCG-3' and 5'-CCATGTTGAAGGTAGCATTTCCATCGAGCTGGTCCTGGAAG-3'. PCR products were subsequently TOPO cloned as per manufacturers' instructions (Invitrogen) and used as substrates for in vitro transcription.
Hmga2 wt/m7 3'UTR
A fragment containing the Hmga2 3'UTR was PCR amplified from the Hmga2 wt or Hmga2 m7 pcDNA3.1 constructs used for transfection. Products were amplified using primers 5'-GCAGAATTCGGGGCGCCGACATTCAATTTC-3' and 5'-TAAGCGGCCGCGCCCACAGAGGCTGTTATGTTTATTG-3'. PCR products were subsequently TOPO cloned as per manufacturers' instructions (Invitrogen). TOPO clone inserts and pcDNA3.1-Hmga2 wt were EcoRI digested and ligated together to generate pcDNA3.1-Hmga2 wt 3'UTR and pcDNA3.1-Hmga2 m7 3'UTR.

Supplementary Material
Supplementary Tables 1-6
